Pharma Report 2012: Get Back in Shape

Share this article:
Pharma Report 2012: Get Back in Shape
Pharma Report 2012: Get Back in Shape

7    Roche    $14.5B     up 5.1%
Global revenue: $46.4B (5th); down 10.4%

R&D spend: $9.1B (2nd), down 5.2%; 19.6% of rev.

Top brands*: Xeloda ($648M), Boniva ($582M), Pegasys ($519M), Valcyte ($325M), Cellcept ($269M)

Planned launches: Pertuzumab (onc.), TDM-1 (onc.)

Promotional spend: $182M (17th); 1.3% of rev.

Patent expirations: Xeloda (2013)

Roche continues to boast a muscular pipeline and a high-performing portfolio of high-science (and high margin) drugs, biologics and diagnostics with negligible exposure to patent expirations (apart from Xeloda, a $648 million drug that loses exclusivity next year). The company recently won approval for Erivedge (vismodegib), for basal cell carcinoma, and just filed pertuzumab for breast cancer. Several other products for various cancers, asthma and atherosclerosis (like CETP inhibitor dalcetrapib) are in late-stage development. The Swiss firm solidified its standing in biologics with its acquisitions of Genentech (2009) and a majority stake in Chugai Pharma (2002), and is now pursuing a hostile takeover of San Diego gene sequencing specialist Illumina.
*Does not include Genentech brands

Back to first page

Page 7 of 21
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?